Lenvakast 10mg Capsule

• Differentiated Thyroid cancer
• Treatment of Kidney Cancer
• Liver cancer
• Treatment of Endometrial Cancer
  

Lenvakast 10 mg Capsule may cause side effects, which often improve as your body adjusts to the medicine and usually don’t require medical attention. However, consult your doctor if they become difficult to manage. Side effects are:

• ​Nausea
  
• Fatigue
• Diarrhea
• Vomiting
• Headache
• Weight loss
• Loss of appetite
• Changes in taste
• Joint pain or muscle pain
• Stomach pain or discomfort
• Hypertension (high blood pressure)
• Blood clotting problems
• Kidney failure
• Heart problems
• Hypothyroidism
• Poor wound healing
• Liver toxicity or failure
• Hemorrhage (bleeding)
• Skin reactions (rash or blisters)
  

• Lenvakast 10mg capsule is a prescription-based medicine that should be administered orally after a doctor's consultation.
• It is advised to take with or without food.

• Lenvakast 10mg capsule works by blocking the action of the enzyme receptor tyrosine kinases (RTKs).
• This enzyme helps develop new blood vessels that nourish cancer cells and help them multiply.
• Lenvakast blocks the function of receptors that aid the growth of blood vessels in cancer cells.
• This helps slow the expansion of the disease to different parts of the body and eventually reduces the size of the tumor.

• It is advised not to miss any scheduled dosage of Lenvakast 10mg capsule.
• In case you miss a dose, consult your doctor immediately.
• Don't overdose to compensate for the missed one. 

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, Dadu R, Sherman EJ, McCue S, Foster NR, Nikiforov YE, Farias TDJ, Norman PJ, Wirth LJ.(2024). Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res 30(17), 3757-3767 - https://pubmed.ncbi.nlm.nih.gov/38922338/
  
• Ruicci, K.M., Deng, Y., Xiao, T. et al. Real-world treatment outcomes and clinicopathologic and molecular determinants of response to first-line lenvatinib in patients with advanced follicular cell-derived thyroid cancer. (2025). BJC Rep 41(3) - https://pubmed.ncbi.nlm.nih.gov/40461800/
  
• Sharma, S., Nazar, A. H., Mishra, P., et al. (2025). A new therapeutic paradigm: Radioiodine combined with lenvatinib for radioiodine‑avid metastatic well‑differentiated thyroid cancer. Nuclear Medicine Communications - https://pubmed.ncbi.nlm.nih.gov/40165683/
  
• Soll, D., Bischoff, P., Frisch, A. et al. (2024). First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study. BMC Endocr Disord - https://pubmed.ncbi.nlm.nih.gov/38383419/
  
• Yokota T, Hamauchi S, Kawakami T, Fushiki K. (2024). Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer. Invest New Drugs 361-368 - https://pubmed.ncbi.nlm.nih.gov/38809355/
  
• Yu, Z., Leng, B., You, R., et al. (2025). Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib‑insensitive patients with unresectable hepatocellular carcinoma: A retrospective study. Investigational New Drugs, 43(1), 93–100 - https://pubmed.ncbi.nlm.nih.gov/39762642/